Ординатура / Офтальмология / Английские материалы / Macular Degeneration_Penfold, Provis_2005
.pdf
Chapter 10 Clinical Strategies for Diagnosis and Treatment of AMD: Implications from Research |
199 |
Smith W, Mitchell P, Wang JJ (1997) Gender, oestrogen, hormone replacement and age-related macular degeneration: results from the Blue Mountains Eye Study. Aust NZ J Ophthalmol 25 (Suppl 1) : S13–S15
Snow KK, Seddon JM (1999) Do age-related macular degeneration and cardiovascular disease share common antecedents? Ophthalmic Epidemiol 6 : 125–143 Spaide RF, Sorenson J, Maranan L (2003) Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovas-
cularization. Ophthalmology 110 : 1517–1525
Spraul CW, Lang GE, Lang GK (1998) [Value of optical coherence tomography in diagnosis of age-related macular degeneration. Correlation of fluorescein angiography and OCT findings]. Klin Monatsbl Augenheilkd 212 : 141–148
Staurenghi G, Orzalesi N, La Capria A,Aschero M (1998) Laser treatment of feeder vessels in subfoveal choroidal neovascular membranes: a revisitation using dynamic indocyanine green angiography. Ophthalmology 105 : 2297–2305
Steen B, Sejersen S, Berglin L, Seregard S, Kvanta A (1998) Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39 : 2194–2200
Stone TW, Sternberg P Jr (2002) Submacular surgery trials update. Ophthalmol Clin North Am 15 : 479–488
Strunnikova N, Baffi J, Gonzalez A, Silk W, Cousins SW, Csaky KG (2001) Regulated heat shock protein 27 expression in human retinal pigment epithelium. Invest Ophthalmol Vis Sci 42 : 2130–2138
Strunnikova NV, Baffi J, Zhang C, et al. (2003) Cellular and molecular responses to sublethal oxidative injury in retinal pigment epithelial cells (RPE). Invest Ophthalmol Vis Sci E (Abstract 3145)
Stur M, Tittl M, Reitner A, Meisinger V (1996) Oral zinc and the second eye in age-related macular degeneration. Invest Ophthalmol Vis Sci 37 : 1225–1235
Submacular Surgery Trials Pilot Study (2000a) Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: 1. Ophthalmic outcomes submacular surgery trials pilot study report number 1. Am J Ophthalmol 130 : 387–407
Submacular Surgery Trials Pilot Study (2000b) Submacular surgery trials randomized pilot trial of laser photocoagulation versus surgery for recurrent choroidal neovascularization secondary to age-related macular degeneration: 2. Quality of life outcomes submacular surgery trials pilot study report number 2. Am J Ophthalmol 130 : 408–418
Subramanian ML, Reichel E (2003) Current indications of transpupillary thermotherapy for the treatment of posterior segment diseases. Curr Opin Ophthalmol 14 : 155–158
Sullivan P, Filsecker L, Sears J (2002) Limited macular translocation with scleral retraction suture. Br J Ophthalmol 86 : 434–439
Suner IJ, Espinosa-Heidmann DG, Marin-Castano ME, Hernandez EP, Pereira-Simon S, Cousins SW (2004) Nicotine increases size and severity of experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 45 : 311–317
Takahashi K, Saishin Y, Saishin Y, Mori K,Ando A,Yamamoto S, Oshima Y, Nambu H, Melia MB, Bingaman DP, Campochiaro PA (2003) Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 44 : 409–415
TAP Study Group (1999) Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 117 : 1329–1345
TAP Study Group and VIP Study Group (Verteporfin Roundtable 2000 and 2001 Participants) (2002) Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22 : 6–18
Taylor HR, Tikellis G, Robman LD, McCarty CA, McNeil JJ (2002) vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ 325 : 11
Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D (1998) Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18 : 2567–2573
Teikari JM, Laatikainen L, Virtamo J, Haukka J, Rautalahti M, Liesto K, Albanes D, Taylor P, Heinonen OP (1998) Six-year supplementation with alpha-tocoph- erol and beta-carotene and age-related maculopathy. Acta Ophthalmol Scand 76 : 224–229
Terasaki H (2001) Rescue of retinal function by macular translocation surgery in age-related macular degeneration and other diseases with subfoveal choroidal neovascularization. Nagoya J Med Sci 64 : 1–9
Tosetti F, Ferrari N, De Flora S, Albini A (2002) Angioprevention”: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16 : 2–14 Toth CA, Freedman SF (2001) Macular translocation with 360-degree peripheral retinectomy impact of technique and surgical experience on visual out-
comes. Retina 21 : 293–303
Tozer GM,Kanthou C,Parkins CS,Hill SA (2002) The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol 83 : 21–38
Tracy RP (2003) Inflammation, the metabolic syndrome and cardiovascular risk. Int J Clin Pract Suppl 10–17 Valmaggia C, Ries G, Ballinari P (2002) Radiotherapy for subfoveal choroidal neovascularization in agerelated macular degeneration: a randomized clinical
trial. Am J Ophthalmol 133 : 521–529
Vander JF, Federman JL, Greven C, Slusher MM, Gabel VP (1991) Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmology 98 : 23–27
200 Scott W. Cousins, Karl G. Csaky, Diego G. Espinosa-Heidmann
VIP (Verteporfin in Photodynamic Therapy) Study Group (2001) Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization–verteporfin in photodynamic therapy report 2. Am J Ophthalmol 131 : 541–560
Vizcarra C (2003) New perspectives and emerging therapies for immune-mediated inflammatory disorders. J Infus Nurs 26 : 319–325
Walsh DA, Pearson CI (2001) Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 3 : 147–153
Weimann JM, Charlton CA, Brazelton TR, Hackman RC, Blau HM (2003) Contribution of transplanted bone marrow cells to Purkinje neurons in human adult brains. Proc Natl Acad Sci USA 100 : 2088–2093
Winkler BS, Boulton ME, Gottsch JD, Sternberg P (1999) Oxidative damage and age-related macular degeneration. Mol Vis 5 : 32
Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22 : 1–29
Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71 : 705–711
Wormald R, Evans J, Smeeth L, Henshaw K (2003) Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev CD002030
Yamamoto Y (2003) Measurement of blood flow velocity in feeder vessels of choroidal neovascularization by a scanning laser ophthalmoscope and image analysis system. Jpn J Ophthalmol 47 : 53–58
Yates JR, Moore AT (2000) Genetic susceptibility to age related macular degeneration. J Med Genet 37 : 83–87 York J, Glaser B, Murphy R (2000) High-speed ICG. Used for pinpoint laser treatment of feeder vessels in
wet AMD. J Ophthalmic Nurs Technol 19 : 66–67 Young RW (1987) Pathophysiology of age-related macu-
lar degeneration. Surv Ophthalmol 31 : 291–306 Zarbin MA (1998) Age-related macular degeneration:
review of pathogenesis. Eur J Ophthalmol 8 : 199–206 Zimmer-Galler IE, Bressler NM, Bressler SB (1995)
Treatment of choroidal neovascularization: updated information from recent macular photocoagulation study group reports. Int Ophthalmol Clin 35 : 37–57
Subject Index
A
angiogenesis 180 animal models 113
–baboon 155
–marmoset 155
–monkey 113
–mouse 114, 116, 150, 173
–rabbit 114
–rat 114, 116, 139, 150 antioxidants 124, 126, 173 apolipoprotein E (APOE) 72 ascorbic acid 138 astrocytes 12
atrophic macular degeneration (see also geographic atrophy) 37, 167
autoantibody 35
B basal
–laminar deposit 167
–linear deposit 167
Beaver Dam Eye Study 53, 80, 82 Best disease 68, 70, 117
bipolar cell 9 blood-retinal barrier 26, 30
bone marrow progenitor 182 Bruch’s membrane 54, 55, 167, 169
C
cell death (see also photoreceptor loss) 140
choroidal neovascularization 37, 38 choroidal new vessels
–growth factor-induced 114
–laser-induced 114, 115 clinical trial 46
–anti-angiogenic drugs 186
–anti-inflammatory 185
–gene therapy 188
–laser 184, 185, 171
–photodynamic therapy 184
–radiation 184
–rheopheresis 172
–surgery 188
–transpupillary thermotherapy 185
–VEGF 187
cone 4, 18
cystoid degeneration 160
D degeneration
–atrophic macular 37, 167
–cystoid 160
–disciform 48
–dry macular 37
–neovascular macular 37, 178
–peripheral 150, 151, 157, 158
–wet macular 37
disciform degeneration 48 DNA damage 125
Down’s syndrome 131
Doyne honeycomb dystrophy 71 drusen 31, 34, 37, 70, 125, 167, 170
– biogenesis 32
dry macular degeneration 37
E
early onset maculopathy 67, 69 electroretinogram 134 estrogen deficiency 174, 175
F
Fibulin family 70, 71 fovea 1, 2
–acuity 26
–anatomy 1
–avascular zone 5
–bipolar cells 17
–blood vessels 12, 19, 25
–comparative anatomy 14–17
–cone density 26, 47
–development 25
–dimensions 9
–ganglion cells 17
–glia 12
–position 3
–rods 47
foveola 2
free radicals 125
G
ganglion cell 6, 9
–density 6
–distribution 11
–midget 17 genetic study
–family 64, 66
–identification of genes 65
–linkage analysis 65, 66
–sibling 64, 168
–twins 64, 168
geographic atrophy 36, 48 giant cells 33
glutamate 141
–toxicity 144
–transporters 143 glutathione 128 GSH-GSSG cycle 129
H
Human Genome Project 63
I
ICAM-1 27 immunological factor 117 incidence 79, 82 inflammation 86, 178, 180
–CD45 40
–ICAM-1 30
–MHC II 30
inherited maculopathy 68
L
L/M cone, relative numbers 16 laser-induced choroidal new vessels
114, 115 lipid 125
lipofuscin 53, 169
M
macrophages 190 macula 1–3, 25 macular
–degeneration
–– atrophic 37
–– dry 37
–– incidence 79
–– neovascular 37
–– population studies 80
–– prevalence 79, 80
–– wet 37
–pigment 52, 138 maculopathy
–early onset 67, 69
–inherited 67
202 Subject Index
Mallatia Leventinese dystrophy 71 |
– |
stress 150, 162 |
– |
in China 107 |
||
manganese 137 |
– |
types 4 |
– |
inheritance 82, 109 |
||
metallothionein 136 |
physiological stress 39 |
– |
iris color 90 |
|||
microarray 73 |
pigmentary disturbance 30 |
– |
light exposure 89, 109 |
|||
microglia 12, 29, 33 |
population study 80, 103 |
– |
myopia 90 |
|||
microphages 33 |
prevalence 79, 80, 105 |
– |
obesity 86 |
|||
midget pathway 10 |
– |
age 194 |
– |
occupation 92, 109 |
||
– |
M/L cones 11 |
– |
ethnicity 81 |
– |
physical activity 88 |
|
mitochondria 154 |
– |
gender 104 |
– |
pulmonary disease 85, 111 |
||
mitochondrial DNA 140 |
– |
in China 103 |
– |
smoking 87, 109, 125 |
||
morbidity 83 |
– |
regional 105, 108 |
– |
socioeconomic 92 |
||
mouse models 117 |
proteomics 74 |
– |
UV radiation 89 |
|||
Müller cells 12, 13, 129–131, 134, 135, |
public health 83 |
– X-rays 90 |
||||
|
142, 143, 154, 158, 190 |
R |
|
|
rod 4, 18 |
|
– |
metabolic functions 141 |
|
|
S |
|
|
N |
|
radial drusen 71 |
|
|||
|
redox reaction 123 |
S cone pathway 10 |
||||
neovascular macular degeneration 37, |
retinal |
scorbic acid 132 |
||||
|
178 |
– |
degeneration slow gene (RDS) 67 |
selenium 137 |
||
neuroprotection 149, 151–153, 155, 163 |
– |
imaging |
serology 35 |
|||
nutritional supplementation 170 |
– |
– |
fluorescein angiography 179 |
single nucleotide polymorphism 73 |
||
O |
|
– |
– |
optical coherent tomography |
Sorsby’s fundus dystrophy 70, 117 |
|
|
|
176 |
Stargardt’s disease 69, 117 |
|||
opsin 5 |
– |
– |
scanning laser ophthalmoscopy |
superoxide 131 |
||
oxidative damage 123 |
|
176 |
T |
|
||
P |
|
– |
– |
scanning laser polarimetry 177 |
|
|
|
– |
pigmented epithelium 13, 53, 54, |
taurine 133, 135 |
|||
Paraoxonase gene 73 |
|
128, 169 |
triamcinolone acetonide 27, 185 |
|||
PEDF 116 |
– |
– |
loss 53 |
V |
|
|
peripheral degeneration 150, 151, 157, |
– |
– |
transport 56 |
|
||
|
158 |
– |
vascularization 38 |
vasculogenesis 181 |
||
photoreceptor 138 |
– |
vasculature 158 |
VEGF 116 |
|||
– |
cone survival 48 |
retinoid cycle 56, 57 |
visual |
|||
– |
cones 6, 8 |
risk factors 82 |
– |
acuity |
||
– |
dark adaptation 54, 55 |
– |
age 82, 83, 105, 109 |
– |
– China (AMD) 107 |
|
– |
density 7, 48 |
– |
alcohol 87, 110 |
– |
cortex 19 |
|
– |
distribution at fovea 3 |
– |
arthritis 86 |
vitamin |
||
– |
dysfunction 51, 52, 54 |
– |
atherosclerosis 84 |
– |
A 56 |
|
– |
early changes 46 |
– |
blood pressure 83, 111 |
– |
E 132, 133 |
|
– |
loss 46, 47, 52, 150, 163, 164 |
– |
caffeine 88 |
W |
|
|
– |
M/L cones 7 |
– |
cataract surgery 91 |
|
||
– |
number 4 |
– |
diabetes 86 |
wet macular degeneration 37 |
||
– rods 6, 8 |
– diet 89 |
WHO 103 |
||||
– |
– loss 47, 49 |
– |
ethnicity 109 |
Z |
|
|
– |
S cones 6, 7 |
– |
gout 86 |
|
||
– |
scotopic sensitivity 55 |
– |
hormone replacement therapy 88 |
zinc 136 |
||
– |
sensitivity 51, 53, 54 |
– |
hyperopia 90 |
|
|
|
Printing: Saladruck, Berlin
Binding: Stein+Lehmann, Berlin